ReviewStem cell reviews and reports2025
Revitalizing Vision: Eye Drops and Corneal Limbal Stem Cells Survival.
Review in Stem cell reviews and reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Targeted nanomedicine strategies for Alzheimer's disease therapy.Discover nano · 2026Review
- The role of microRNAs in modulating Wnt signaling pathway dynamics and their therapeutic implications in non-small cell lung cancer.Discover oncology · 2026Review
- Innovative Applications of Nanomaterials in the Diagnosis and Treatment of Ocular Diseases: Targeted Delivery, Intelligent Therapy, Diagnostic Breakthroughs, and Synergistic Strategies with Stem Cells and Biomaterials.International journal of nanomedicine · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the quest to transform vision care, researchers have been investigating novel methods to boost the efficacy of eye drops and enhance the survival of corneal limbal stem cells. Aimed at rejuvenating vision, these innovations seek to tackle a range of ocular conditions and restore sight to those in need. This article examines the most recent advancements in eye drops and corneal limbal stem cells, highlighting their potential to revolutionize ophthalmology. Findings from various studies indicate that the drive to rejuvenate vision has resulted in significant progress within the field of ophthalmology, especially regarding eye drops and corneal limbal stem cells. By improving the effectiveness of eye drops and increasing the survival rates of CLSCs, researchers are creating pathways for more sustainable and effective treatment options. These advancements offer great hope for patients experiencing various ocular issues, suggesting a future where vision restoration is attainable. As research continues to refine these strategies, we can look forward to an era marked by better visual outcomes and an enhanced quality of life for many individuals around the world.
Indexed as
Identifiers
39786675What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.